Apogee Therapeutics announced a financing partnership with Blackstone Life Sciences that could provide up to $1.3 billion in non-dilutive capital. The funding is intended to support advancement and potential commercialization of lead drug candidate zumilokibart. The deal strengthens the company's balance sheet and reduces near-term financing risk.
Apogee Therapeutics announced a financing partnership with Blackstone Life Sciences that could provide up to $1.3 billion in non-dilutive capital. The funding is intended to support advancement and potential commercialization of lead drug candidate zumilokibart. The deal strengthens the company's balance sheet and reduces near-term financing risk.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
